Inflammation as potential target for therapy to target residual risk post ACS - PACE-CME

Inflammation as potential target for therapy to target residual risk post ACS

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Extra work of checking device data weekly does not translate into benefit for HF patient
Extra work of checking device data weekly does not translate into benefit for HF patient
ESC 2016
Extra work of checking device data weekly does not translate into benefit for HF patient
- Martin Cowie, MD
Heart Failure news from ESC 2016 at a glance
Heart Failure news from ESC 2016 at a glance
ESC 2016
Heart Failure news from ESC 2016 at a glance
- Prof. Mariell Jessup
No indication for difference in efficacy between potent platelet inhibitors after PCI
No indication for difference in efficacy between potent platelet inhibitors after PCI
ESC 2016
No indication for difference in efficacy between potent platelet inhibitors after PCI
- Steen Dalby Kristensen, MD
Iron deficiency in the new HF guidelines
Iron deficiency in the new HF guidelines
ESC 2016
Iron deficiency in the new HF guidelines
- Peter van der Meer, MD